Endocrine Abstracts

Background: The development of a new syringe for lanreotide Autogel, in conjunction with patients, caregivers and HCPs, identified and integrated several upgrades to the previous design that could improve patient care.Aims: To better understand which attributes are pertinent to users, and how user preferences can be optimally assessed, we conducted a systematic literature review of relevant studies of pre-filled devices.Methods: Pu...

Introduction: PRIMARYS provided evidence for TVR with monthly LAN-ATG 120 mg in treatment-naïve acromegalic patients (63% achieved TVR ≥20% with a favourable safety profile). To help clinicians with therapeutic management of acromegaly, tumour responsive over time needs to be further explored.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patients with pituitary macroade...

Introduction: The PRIMARYS study demonstrated primary treatment with lanreotide Autogel 120 mg could achieve favourable tumour and hormone response rates in a large cohort of acromegalic patients. Here, we further interrogate the PRIMARYS database on the relationship between the tumour volume responsiveness and hormonal control.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patient...

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...